> top > docs > PMC:7121452 > spans > 12139-17415 > annotations

PMC:7121452 / 12139-17415 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
387 55-63 Disease denotes Covid-19 MESH:C000657245
399 150-154 Gene denotes ACE2 Gene:59272
400 188-198 Species denotes SARS-CoV-2 Tax:2697049
401 282-290 Species denotes patients Tax:9606
402 357-365 Species denotes patients Tax:9606
403 429-437 Species denotes patients Tax:9606
404 706-714 Species denotes patients Tax:9606
405 322-330 Disease denotes Covid-19 MESH:C000657245
406 382-405 Disease denotes cardiovascular diseases MESH:D002318
407 446-463 Disease denotes myocardial injury MESH:D009202
408 476-493 Disease denotes myocardial stress MESH:D000079225
409 501-515 Disease denotes cardiomyopathy MESH:D009202
428 878-886 Species denotes patients Tax:9606
429 988-996 Species denotes patients Tax:9606
430 1158-1166 Species denotes patients Tax:9606
431 1564-1572 Species denotes patients Tax:9606
432 951-960 Chemical denotes Quinapril MESH:D000077583
433 1051-1060 Chemical denotes quinapril MESH:D000077583
434 734-747 Disease denotes heart failure MESH:D006333
435 843-856 Disease denotes heart failure MESH:D006333
436 863-877 Disease denotes critically ill MESH:D016638
437 892-900 Disease denotes Covid-19 MESH:C000657245
438 1022-1035 Disease denotes heart failure MESH:D006333
439 1124-1131 Disease denotes TRED-HF
440 1172-1185 Disease denotes heart failure MESH:D006333
441 1335-1357 Disease denotes dilated cardiomyopathy MESH:D002311
442 1425-1446 Disease denotes myocardial infarction MESH:D009203
443 1545-1554 Disease denotes mortality MESH:D003643
444 1604-1621 Disease denotes myocardial injury MESH:D009202
445 1638-1646 Disease denotes Covid-19 MESH:C000657245
451 2098-2105 Species denotes patient Tax:9606
452 2293-2300 Species denotes patient Tax:9606
453 2516-2524 Species denotes patients Tax:9606
454 1797-1809 Disease denotes hypertension MESH:D006973
455 2530-2538 Disease denotes Covid-19 MESH:C000657245
466 2806-2814 Species denotes patients Tax:9606
467 2930-2938 Species denotes patients Tax:9606
468 3019-3027 Species denotes patients Tax:9606
469 3103-3111 Species denotes patients Tax:9606
470 3200-3208 Species denotes patients Tax:9606
471 2820-2842 Disease denotes chronic kidney disease MESH:D051436
472 2879-2893 Disease denotes kidney disease MESH:D007674
473 2944-2952 Disease denotes Covid-19 MESH:C000657245
474 3036-3050 Disease denotes critically ill MESH:D016638
475 3136-3155 Disease denotes acute kidney injury MESH:D058186
482 3532-3536 Gene denotes ACE2 Gene:59272
483 3666-3674 Species denotes patients Tax:9606
484 3924-3932 Species denotes patients Tax:9606
485 3617-3625 Disease denotes Covid-19 MESH:C000657245
486 3759-3767 Disease denotes Covid-19 MESH:C000657245
487 3938-3946 Disease denotes Covid-19 MESH:C000657245
490 4230-4241 Chemical denotes Aldosterone MESH:D000450
491 4195-4203 Disease denotes Covid-19 MESH:C000657245
495 4251-4255 Gene denotes ACE2 Gene:59272
496 4344-4354 Species denotes SARS-CoV-2 Tax:2697049
497 4386-4394 Disease denotes Covid-19 MESH:C000657245
501 4482-4486 Gene denotes ACE2 Gene:59272
502 4542-4550 Species denotes patients Tax:9606
503 4556-4564 Disease denotes Covid-19 MESH:C000657245
506 4660-4666 Species denotes humans Tax:9606
507 4732-4740 Disease denotes Covid-19 MESH:C000657245
512 4853-4857 Gene denotes ACE2 Gene:59272
513 4847-4852 Species denotes human Tax:9606
514 4870-4878 Chemical denotes losartan MESH:D019808
515 4882-4890 Disease denotes Covid-19 MESH:C000657245
519 4943-4951 Species denotes patients Tax:9606
520 4978-4991 Disease denotes heart failure MESH:D006333
521 5004-5025 Disease denotes myocardial infarction MESH:D009203
524 5179-5187 Species denotes patients Tax:9606
525 5268-5276 Disease denotes Covid-19 MESH:C000657245

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T48 616-622 Body_part denotes kidney http://purl.org/sig/ont/fma/fma7203
T49 627-637 Body_part denotes myocardium http://purl.org/sig/ont/fma/fma9462
T50 734-739 Body_part denotes heart http://purl.org/sig/ont/fma/fma7088
T51 843-848 Body_part denotes heart http://purl.org/sig/ont/fma/fma7088
T52 961-966 Body_part denotes Heart http://purl.org/sig/ont/fma/fma7088
T53 1022-1027 Body_part denotes heart http://purl.org/sig/ont/fma/fma7088
T54 1172-1177 Body_part denotes heart http://purl.org/sig/ont/fma/fma7088
T55 2166-2171 Body_part denotes blood http://purl.org/sig/ont/fma/fma9670
T56 2350-2355 Body_part denotes blood http://purl.org/sig/ont/fma/fma9670
T57 2642-2647 Body_part denotes blood http://purl.org/sig/ont/fma/fma9670
T58 2828-2834 Body_part denotes kidney http://purl.org/sig/ont/fma/fma7203
T59 2879-2885 Body_part denotes kidney http://purl.org/sig/ont/fma/fma7203
T60 3142-3148 Body_part denotes kidney http://purl.org/sig/ont/fma/fma7203
T61 4978-4983 Body_part denotes heart http://purl.org/sig/ont/fma/fma7088

LitCovid-PD-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T25 616-622 Body_part denotes kidney http://purl.obolibrary.org/obo/UBERON_0002113
T26 627-637 Body_part denotes myocardium http://purl.obolibrary.org/obo/UBERON_0002349
T27 734-739 Body_part denotes heart http://purl.obolibrary.org/obo/UBERON_0000948
T28 843-848 Body_part denotes heart http://purl.obolibrary.org/obo/UBERON_0000948
T29 961-966 Body_part denotes Heart http://purl.obolibrary.org/obo/UBERON_0000948
T30 1022-1027 Body_part denotes heart http://purl.obolibrary.org/obo/UBERON_0000948
T31 1172-1177 Body_part denotes heart http://purl.obolibrary.org/obo/UBERON_0000948
T32 2166-2171 Body_part denotes blood http://purl.obolibrary.org/obo/UBERON_0000178
T33 2350-2355 Body_part denotes blood http://purl.obolibrary.org/obo/UBERON_0000178
T34 2642-2647 Body_part denotes blood http://purl.obolibrary.org/obo/UBERON_0000178
T35 2828-2834 Body_part denotes kidney http://purl.obolibrary.org/obo/UBERON_0002113
T36 2879-2885 Body_part denotes kidney http://purl.obolibrary.org/obo/UBERON_0002113
T37 3142-3148 Body_part denotes kidney http://purl.obolibrary.org/obo/UBERON_0002113
T38 4978-4983 Body_part denotes heart http://purl.obolibrary.org/obo/UBERON_0000948

LitCovid_AGAC

Id Subject Object Predicate Lexical cue
p78841s8 4473-4481 PosReg denotes increase
p78841s9 4482-4486 Protein denotes ACE2
p78841s10 4487-4497 MPA denotes expression

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T56 188-196 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T57 382-405 Disease denotes cardiovascular diseases http://purl.obolibrary.org/obo/MONDO_0004995
T58 457-463 Disease denotes injury http://purl.obolibrary.org/obo/MONDO_0021178
T59 734-747 Disease denotes heart failure http://purl.obolibrary.org/obo/MONDO_0005252
T60 843-856 Disease denotes heart failure http://purl.obolibrary.org/obo/MONDO_0005252
T61 961-974 Disease denotes Heart Failure http://purl.obolibrary.org/obo/MONDO_0005252
T62 1010-1035 Disease denotes symptomatic heart failure http://purl.obolibrary.org/obo/MONDO_0005254
T63 1022-1035 Disease denotes heart failure http://purl.obolibrary.org/obo/MONDO_0005252
T64 1172-1185 Disease denotes heart failure http://purl.obolibrary.org/obo/MONDO_0005252
T65 1335-1357 Disease denotes dilated cardiomyopathy http://purl.obolibrary.org/obo/MONDO_0005021
T66 1343-1357 Disease denotes cardiomyopathy http://purl.obolibrary.org/obo/MONDO_0004994
T67 1425-1446 Disease denotes myocardial infarction http://purl.obolibrary.org/obo/MONDO_0005068
T68 1615-1621 Disease denotes injury http://purl.obolibrary.org/obo/MONDO_0021178
T69 1797-1809 Disease denotes hypertension http://purl.obolibrary.org/obo/MONDO_0005044
T70 2153-2180 Disease denotes increases in blood pressure http://purl.obolibrary.org/obo/MONDO_0005044
T71 2820-2842 Disease denotes chronic kidney disease http://purl.obolibrary.org/obo/MONDO_0005300
T72 2828-2842 Disease denotes kidney disease http://purl.obolibrary.org/obo/MONDO_0001343|http://purl.obolibrary.org/obo/MONDO_0005240
T74 2871-2893 Disease denotes chronic kidney disease http://purl.obolibrary.org/obo/MONDO_0005300
T75 2879-2893 Disease denotes kidney disease http://purl.obolibrary.org/obo/MONDO_0001343|http://purl.obolibrary.org/obo/MONDO_0005240
T77 3136-3155 Disease denotes acute kidney injury http://purl.obolibrary.org/obo/MONDO_0002492
T78 3149-3155 Disease denotes injury http://purl.obolibrary.org/obo/MONDO_0021178
T79 4344-4352 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T80 4866-4869 Disease denotes ARB http://purl.obolibrary.org/obo/MONDO_0012733
T81 4978-4991 Disease denotes heart failure http://purl.obolibrary.org/obo/MONDO_0005252
T82 5004-5025 Disease denotes myocardial infarction http://purl.obolibrary.org/obo/MONDO_0005068

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T131 439-445 http://purl.obolibrary.org/obo/CLO_0001658 denotes active
T132 616-622 http://purl.obolibrary.org/obo/UBERON_0002113 denotes kidney
T133 616-622 http://www.ebi.ac.uk/efo/EFO_0000927 denotes kidney
T134 616-622 http://www.ebi.ac.uk/efo/EFO_0000929 denotes kidney
T135 627-637 http://purl.obolibrary.org/obo/UBERON_0002349 denotes myocardium
T136 734-739 http://purl.obolibrary.org/obo/UBERON_0000948 denotes heart
T137 734-739 http://purl.obolibrary.org/obo/UBERON_0007100 denotes heart
T138 734-739 http://purl.obolibrary.org/obo/UBERON_0015228 denotes heart
T139 734-739 http://www.ebi.ac.uk/efo/EFO_0000815 denotes heart
T140 843-848 http://purl.obolibrary.org/obo/UBERON_0000948 denotes heart
T141 843-848 http://purl.obolibrary.org/obo/UBERON_0007100 denotes heart
T142 843-848 http://purl.obolibrary.org/obo/UBERON_0015228 denotes heart
T143 843-848 http://www.ebi.ac.uk/efo/EFO_0000815 denotes heart
T144 961-966 http://purl.obolibrary.org/obo/UBERON_0000948 denotes Heart
T145 961-966 http://purl.obolibrary.org/obo/UBERON_0007100 denotes Heart
T146 961-966 http://purl.obolibrary.org/obo/UBERON_0015228 denotes Heart
T147 961-966 http://www.ebi.ac.uk/efo/EFO_0000815 denotes Heart
T148 1022-1027 http://purl.obolibrary.org/obo/UBERON_0000948 denotes heart
T149 1022-1027 http://purl.obolibrary.org/obo/UBERON_0007100 denotes heart
T150 1022-1027 http://purl.obolibrary.org/obo/UBERON_0015228 denotes heart
T151 1022-1027 http://www.ebi.ac.uk/efo/EFO_0000815 denotes heart
T152 1073-1074 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T153 1172-1177 http://purl.obolibrary.org/obo/UBERON_0000948 denotes heart
T154 1172-1177 http://purl.obolibrary.org/obo/UBERON_0007100 denotes heart
T155 1172-1177 http://purl.obolibrary.org/obo/UBERON_0015228 denotes heart
T156 1172-1177 http://www.ebi.ac.uk/efo/EFO_0000815 denotes heart
T157 1394-1395 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T158 1514-1517 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T159 2022-2023 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T160 2078-2079 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T161 2166-2171 http://purl.obolibrary.org/obo/UBERON_0000178 denotes blood
T162 2166-2171 http://www.ebi.ac.uk/efo/EFO_0000296 denotes blood
T163 2350-2355 http://purl.obolibrary.org/obo/UBERON_0000178 denotes blood
T164 2350-2355 http://www.ebi.ac.uk/efo/EFO_0000296 denotes blood
T165 2383-2384 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T166 2567-2568 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T167 2583-2593 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T168 2642-2647 http://purl.obolibrary.org/obo/UBERON_0000178 denotes blood
T169 2642-2647 http://www.ebi.ac.uk/efo/EFO_0000296 denotes blood
T170 2828-2834 http://purl.obolibrary.org/obo/UBERON_0002113 denotes kidney
T171 2828-2834 http://www.ebi.ac.uk/efo/EFO_0000927 denotes kidney
T172 2828-2834 http://www.ebi.ac.uk/efo/EFO_0000929 denotes kidney
T173 2879-2885 http://purl.obolibrary.org/obo/UBERON_0002113 denotes kidney
T174 2879-2885 http://www.ebi.ac.uk/efo/EFO_0000927 denotes kidney
T175 2879-2885 http://www.ebi.ac.uk/efo/EFO_0000929 denotes kidney
T176 2979-2981 http://purl.obolibrary.org/obo/CLO_0050050 denotes S1
T177 3142-3148 http://purl.obolibrary.org/obo/UBERON_0002113 denotes kidney
T178 3142-3148 http://www.ebi.ac.uk/efo/EFO_0000927 denotes kidney
T179 3142-3148 http://www.ebi.ac.uk/efo/EFO_0000929 denotes kidney
T180 3784-3785 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T181 3848-3850 http://purl.obolibrary.org/obo/CLO_0008922 denotes S2
T182 3848-3850 http://purl.obolibrary.org/obo/CLO_0050052 denotes S2
T183 4302-4312 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T184 4360-4365 http://purl.obolibrary.org/obo/NCBITaxon_10239 denotes virus
T185 4660-4666 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes humans
T186 4776-4780 http://purl.obolibrary.org/obo/UBERON_0000473 denotes test
T187 4847-4852 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T188 4978-4983 http://purl.obolibrary.org/obo/UBERON_0000948 denotes heart
T189 4978-4983 http://purl.obolibrary.org/obo/UBERON_0007100 denotes heart
T190 4978-4983 http://purl.obolibrary.org/obo/UBERON_0015228 denotes heart
T191 4978-4983 http://www.ebi.ac.uk/efo/EFO_0000815 denotes heart

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T127 268-278 Chemical denotes inhibitors http://purl.obolibrary.org/obo/CHEBI_35222
T128 561-571 Chemical denotes inhibitors http://purl.obolibrary.org/obo/CHEBI_35222
T129 951-960 Chemical denotes Quinapril http://purl.obolibrary.org/obo/CHEBI_8713
T130 1051-1060 Chemical denotes quinapril http://purl.obolibrary.org/obo/CHEBI_8713
T131 1129-1131 Chemical denotes HF http://purl.obolibrary.org/obo/CHEBI_141438|http://purl.obolibrary.org/obo/CHEBI_29228
T133 1294-1304 Chemical denotes inhibitors http://purl.obolibrary.org/obo/CHEBI_35222
T134 1379-1389 Chemical denotes inhibitors http://purl.obolibrary.org/obo/CHEBI_35222
T135 1705-1715 Chemical denotes inhibitors http://purl.obolibrary.org/obo/CHEBI_35222
T136 1736-1746 Chemical denotes inhibitors http://purl.obolibrary.org/obo/CHEBI_35222
T137 1852-1862 Chemical denotes inhibitors http://purl.obolibrary.org/obo/CHEBI_35222
T138 2029-2038 Chemical denotes inhibitor http://purl.obolibrary.org/obo/CHEBI_35222
T139 2050-2066 Chemical denotes antihypertensive http://purl.obolibrary.org/obo/CHEBI_35674
T140 2224-2240 Chemical denotes antihypertensive http://purl.obolibrary.org/obo/CHEBI_35674
T141 2751-2761 Chemical denotes inhibitors http://purl.obolibrary.org/obo/CHEBI_35222
T142 3279-3289 Chemical denotes inhibitors http://purl.obolibrary.org/obo/CHEBI_35222
T143 3518-3528 Chemical denotes inhibitors http://purl.obolibrary.org/obo/CHEBI_35222
T144 3564-3569 Chemical denotes drugs http://purl.obolibrary.org/obo/CHEBI_23888
T145 3632-3642 Chemical denotes inhibitors http://purl.obolibrary.org/obo/CHEBI_35222
T146 3848-3850 Chemical denotes S2 http://purl.obolibrary.org/obo/CHEBI_29387
T147 4218-4229 Chemical denotes Angiotensin http://purl.obolibrary.org/obo/CHEBI_2719
T148 4230-4241 Chemical denotes Aldosterone http://purl.obolibrary.org/obo/CHEBI_27584
T149 4458-4468 Chemical denotes inhibitors http://purl.obolibrary.org/obo/CHEBI_35222
T150 4718-4728 Chemical denotes inhibitors http://purl.obolibrary.org/obo/CHEBI_35222
T151 4870-4878 Chemical denotes losartan http://purl.obolibrary.org/obo/CHEBI_6541
T152 4919-4929 Chemical denotes inhibitors http://purl.obolibrary.org/obo/CHEBI_35222
T153 5145-5155 Chemical denotes inhibitors http://purl.obolibrary.org/obo/CHEBI_35222

LitCovid-PD-GO-BP

Id Subject Object Predicate Lexical cue
T9 136-146 http://purl.obolibrary.org/obo/GO_0065007 denotes regulation

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T18 382-405 Phenotype denotes cardiovascular diseases http://purl.obolibrary.org/obo/HP_0001626
T19 734-747 Phenotype denotes heart failure http://purl.obolibrary.org/obo/HP_0001635
T20 843-856 Phenotype denotes heart failure http://purl.obolibrary.org/obo/HP_0001635
T21 961-974 Phenotype denotes Heart Failure http://purl.obolibrary.org/obo/HP_0001635
T22 1022-1035 Phenotype denotes heart failure http://purl.obolibrary.org/obo/HP_0001635
T23 1172-1185 Phenotype denotes heart failure http://purl.obolibrary.org/obo/HP_0001635
T24 1335-1357 Phenotype denotes dilated cardiomyopathy http://purl.obolibrary.org/obo/HP_0001644
T25 1425-1446 Phenotype denotes myocardial infarction http://purl.obolibrary.org/obo/HP_0001658
T26 1797-1809 Phenotype denotes hypertension http://purl.obolibrary.org/obo/HP_0000822
T27 2153-2180 Phenotype denotes increases in blood pressure http://purl.obolibrary.org/obo/HP_0032263
T28 2820-2842 Phenotype denotes chronic kidney disease http://purl.obolibrary.org/obo/HP_0012622
T29 2871-2893 Phenotype denotes chronic kidney disease http://purl.obolibrary.org/obo/HP_0012622
T30 3136-3155 Phenotype denotes acute kidney injury http://purl.obolibrary.org/obo/HP_0001919
T31 4978-4991 Phenotype denotes heart failure http://purl.obolibrary.org/obo/HP_0001635
T32 5004-5025 Phenotype denotes myocardial infarction http://purl.obolibrary.org/obo/HP_0001658

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T42 0-63 Sentence denotes Maintenance of RAAS Inhibitors with Known or Suspected Covid-19
T43 64-321 Sentence denotes Despite these theoretical uncertainties regarding whether pharmacologic regulation of ACE2 may influence the infectivity of SARS-CoV-2, there is clear potential for harm related to the withdrawal of RAAS inhibitors in patients in otherwise stable condition.
T44 322-555 Sentence denotes Covid-19 is particularly severe in patients with underlying cardiovascular diseases,9 and in many of these patients, active myocardial injury,14,54,58-60 myocardial stress,59 and cardiomyopathy59 develop during the course of illness.
T45 556-715 Sentence denotes RAAS inhibitors have established benefits in protecting the kidney and myocardium, and their withdrawal may risk clinical decompensation in high-risk patients.
T46 716-1716 Sentence denotes Although rates of heart failure have been infrequently reported in epidemiologic reports from China to date, the prevalence of heart failure among critically ill patients with Covid-19 in the United States may be high (>40%).59 In the Quinapril Heart Failure Trial, among patients with chronic symptomatic heart failure, withdrawal of quinapril resulted in a progressive decline in clinical status.61 In the TRED-HF trial, among asymptomatic patients with heart failure with recovered left ventricular ejection fraction, the phased withdrawal of medical therapy (including RAAS inhibitors) resulted in rapid relapse of dilated cardiomyopathy.62 In addition, RAAS inhibitors are a cornerstone of therapy after myocardial infarction: maintenance of therapy in the days to weeks after the index event has been shown to reduce early mortality.63 Among patients with unstable clinical status, myocardial injury associated with Covid-19 may pose even higher early risks after withdrawal of RAAS inhibitors.
T47 1717-2006 Sentence denotes Withdrawal of RAAS inhibitors that are being administered for the management of hypertension may be less risky than withdrawal of RAAS inhibitors that are being administered for conditions in which they are considered guideline-directed therapy but may be associated with other challenges.
T48 2007-2181 Sentence denotes Switching from a RAAS inhibitor to another antihypertensive therapy in a stable ambulatory patient may require careful follow-up to avoid rebound increases in blood pressure.
T49 2182-2311 Sentence denotes In addition, selection of dose-equivalent antihypertensive therapies may be challenging in practice and may be patient-dependent.
T50 2312-2718 Sentence denotes Even small and short-lived periods of blood pressure instability after a therapeutic change have been associated with excess cardiovascular risk.64-66 This may be an especially important consideration in patients with Covid-19, which appears to result in a state of RAAS activation,44 and in settings (e.g., China) where baseline blood-pressure control is infrequently reached at the population level.11,12
T51 2719-2843 Sentence denotes The effects of withdrawing RAAS inhibitors or switching treatments are uncertain among patients with chronic kidney disease.
T52 2844-3384 Sentence denotes Although reported rates of chronic kidney disease appear to be low among hospitalized patients with Covid-19 in China (1 to 3%) (Table S1), the prevalence may be higher among patients who are critically ill and among those in other geographic regions.59 Many patients have varying degrees of acute kidney injury during illness.14,67,68 For these high-risk patients, individualized treatment decisions regarding the maintenance of RAAS inhibitors that are guided by hemodynamic status, renal function, and clinical stability are recommended.
T53 3385-3852 Sentence denotes On the basis of the available evidence, we think that, despite the theoretical concerns and uncertainty regarding the effect of RAAS inhibitors on ACE2 and the way in which these drugs might affect the propensity for or severity of Covid-19, RAAS inhibitors should be continued in patients in otherwise stable condition who are at risk for, are being evaluated for, or have Covid-19 (see text box), a position now supported by multiple specialty societies (Table S2).
T54 3853-4150 Sentence denotes Although additional data may further inform the treatment of high-risk patients with Covid-19, clinicians need to be cognizant of the unintended consequences of prematurely discontinuing proven therapies in response to hypothetical concerns that may be based on incomplete experimental evidence.69
T55 4151-4248 Sentence denotes Key Points Related to the Interplay between Covid-19 and the Renin–Angiotensin–Aldosterone System
T56 4249-4403 Sentence denotes • ACE2, an enzyme that physiologically counters RAAS activation, is the functional receptor to SARS-CoV-2, the virus responsible for the Covid-19 pandemic
T57 4404-4564 Sentence denotes • Select preclinical studies have suggested that RAAS inhibitors may increase ACE2 expression, raising concerns regarding their safety in patients with Covid-19
T58 4565-4740 Sentence denotes • Insufficient data are available to determine whether these observations readily translate to humans, and no studies have evaluated the effects of RAAS inhibitors in Covid-19
T59 4741-4890 Sentence denotes • Clinical trials are under way to test the safety and efficacy of RAAS modulators, including recombinant human ACE2 and the ARB losartan in Covid-19
T60 4891-5089 Sentence denotes • Abrupt withdrawal of RAAS inhibitors in high-risk patients, including those who have heart failure or have had myocardial infarction, may result in clinical instability and adverse health outcomes
T61 5090-5276 Sentence denotes • Until further data are available, we think that RAAS inhibitors should be continued in patients in otherwise stable condition who are at risk for, being evaluated for, or with Covid-19

2_test

Id Subject Object Predicate Lexical cue
32227760-32171076-75177451 464-466 32171076 denotes 14
32227760-32211816-75177452 467-469 32211816 denotes 54
32227760-32125452-75177453 473-475 32125452 denotes 60
32227760-32191259-75177454 494-496 32191259 denotes 59
32227760-32191259-75177455 515-517 32191259 denotes 59
32227760-32191259-75177456 941-943 32191259 denotes 59
32227760-8227822-75177457 1114-1116 8227822 denotes 61
32227760-30429050-75177458 1358-1360 30429050 denotes 62
32227760-9631869-75177459 1555-1557 9631869 denotes 63
32227760-15207952-75177460 2460-2462 15207952 denotes 66
32227760-32048163-75177461 2594-2596 32048163 denotes 44
32227760-29449338-75177462 2713-2715 29449338 denotes 11
32227760-29102084-75177463 2716-2718 29102084 denotes 12
32227760-32191259-75177464 3095-3097 32191259 denotes 59
32227760-32171076-75177465 3171-3173 32171076 denotes 14
32227760-32007143-75177466 3174-3176 32007143 denotes 67
32227760-32167524-75177467 3177-3179 32167524 denotes 68
32227760-26643266-75177468 4148-4150 26643266 denotes 69